Aromatase inhibitors in the treatment and prevention of breast cancer.
about
Aromatase inhibitors for uterine fibroidsIntroducing a new section to Breast Cancer Research: endocrinology and hormone therapyOestrogen exposure and breast cancer riskTreatment of Intravenous Leiomyomatosis with Cardiac Extension following Incomplete ResectionBreast cancer chemoprevention: progress and controversy.Aromatase inhibitors and inactivators in breast cancerCurrent strategies for the prevention of breast cancerPotential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.A peptide derived from alpha-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifen.An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer.Nonsteroidal aromatase inhibitors: recent advances.Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.Nutrition and survival after the diagnosis of breast cancer: a review of the evidence.Anti-oestrogenic prevention of breast cancer--the make or break point.The therapeutic potential of aromatase inhibitors.Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell deathDietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studiesSafety issues surrounding the use of aromatase inhibitors in breast cancer.Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.Clinical infrastructures to support proteomic studies of tissue and fluids in breast cancer.Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.The interaction between ER and NFκB in resistance to endocrine therapy.PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.Awareness and current knowledge of breast cancer.Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.Farnesyl transferase inhibitors.The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer.Chemopreventive effects of atractylenolide II on mammary tumorigenesis via activating Nrf2-ARE pathway.Neoadjuvant therapy for ER-positive breast cancers.
P2860
Q24202922-68445FE1-40E1-448E-BAEA-48A934EF6F6AQ24802767-B3C15659-F1E5-4587-AE8B-B13ABBFD6581Q24803498-D2AD7F85-A28A-4C0B-A531-17FD0E3239E8Q26771239-438DE543-E8E1-4019-BF4D-783F66334BD0Q27692587-A6672F13-54F1-4C4A-B65B-ACE9D164131DQ28362331-C3AA5E76-B46A-442D-87CB-383FF91D4064Q33599463-03F66FE0-BC03-4FDB-A4B4-3920A72F18AEQ33847525-78797566-69DC-4392-B153-DBE507598BA7Q34012792-C695C9CC-1A88-4F07-997D-7992C88F1F26Q34156603-20A40A31-6D8E-4B25-9C12-C9054C5EF5BFQ34434006-99A61EE0-C4D2-48B7-8855-7190B2ACE5F9Q34587518-2B8AA99F-FEBF-434D-B54A-22EF4362A21BQ34734021-0623FDEF-D919-4BAA-9E26-816BE0EA5115Q34767869-916CAB0C-4336-419A-B275-BE29AF0409CDQ34932305-79D46666-C6E2-4367-9E93-75B5003D4CDFQ35073327-DED22AFE-010C-4F4D-9DA1-99B5E3CD7B12Q35107727-55502CB6-087E-4884-B8F8-8F359617A284Q35137553-A35697BE-BF29-46D4-9E9B-CE99E710CBE8Q35194446-613488AE-DBE9-4722-AF9B-1AC023114ED0Q35593300-0A848E28-DEC5-460F-83B3-EDE5C9338DA8Q35648512-5B64C77D-A22A-4518-B914-02C3E0218983Q36612045-051155C9-83A9-4B2A-9625-A4BB8C82F7C3Q36695888-6DCF3E42-02EB-4AD1-B49A-7D8460E2CB5FQ36924406-5C9FDB85-13AC-4E4A-BA75-27247262562DQ37444546-6B4EF2EF-068C-44E8-A451-BA15F9F42662Q37531200-B06F0B00-BDE4-4AAD-B698-8D4036E51D81Q42176053-247EF363-62F8-4DAB-BF2C-425CE4BB6997Q44023171-1833A848-4CCA-49CC-9D14-A975CB8CAC95Q46456381-C23E2DDC-3BCA-4B9D-89D9-2EA32ABE66E5Q46838215-235E8BAE-1794-4C4E-B58A-D58447B7D642Q47105785-2B1B012D-30D8-4B00-9915-8230C46B861EQ51320601-FCD79171-5C76-40A0-B7A9-5E7CD53CEB45
P2860
Aromatase inhibitors in the treatment and prevention of breast cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Aromatase inhibitors in the treatment and prevention of breast cancer.
@ast
Aromatase inhibitors in the treatment and prevention of breast cancer.
@en
type
label
Aromatase inhibitors in the treatment and prevention of breast cancer.
@ast
Aromatase inhibitors in the treatment and prevention of breast cancer.
@en
prefLabel
Aromatase inhibitors in the treatment and prevention of breast cancer.
@ast
Aromatase inhibitors in the treatment and prevention of breast cancer.
@en
P1476
Aromatase inhibitors in the treatment and prevention of breast cancer.
@en
P2093
P304
P356
10.1200/JCO.2001.19.3.881
P407
P577
2001-02-01T00:00:00Z